Found 17 Cardiomyopathy trials
A listing of Cardiomyopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study aims to understand the effects of potential familial/genetic links in an otherwise unclear origin of a patient's heart disease.
This study is enrolling newly diagnosed heart failure (within 6 months from diagnosis) patients with no known cause for their heart disease. We are utilizing already used technology, voltage mapping capabilities used in electrophysiology procedures, to more directly target weaker areas of the left and right ventricles. our physicians would …
This study is for those diagnosed with transthyretin-mediated amyloid cardiomyopathy which is a disease caused by change in a protein called transthyretin (TTR). This change can either be sporadic which is known as wild-type (wtATTR-CM) or due to a mutation of the TTR gene which is hereditary (hATTR-CM). In both …
The purpose of this study is to compare the effect of the investigational drug, mavacamten, (MYK-461), to a placebo (an inactive substance) in patients with Non-obstructive Hypertrophic Cardiomyopathy (nHCM).
This is a prospective, multicenter observational study to identify clinical, genetic and imaging predictors of clinical outcome in patients with suspected non-compaction cardiomyopathy Many healthy people have increased trabeculations without consequences, however, some may develop blood clots, heart rhythm disorders or heart failure later in life. Currently we cannot predict …
This study will focus on fat buildup inside the heart muscle, a newly recognized factor that makes patients vulnerable to such fast heart rates, or ventricular tachycardia, after a heart attack. This work may identify more successful strategies for curing dangerously fast heart rates. Adult subjects with prior history of …
This patisiran expanded access protocol (EAP) is an open-label, multicenter, single-arm study designed to provide pre-approval access to investigational patisiran for patients with ATTR amyloidosis with cardiomyopathy who, at baseline, have an inadequate response to or cannot tolerate standard of care. An intravenous infusion of study drug (patisiran 0.3 mg/kg) …
PURPOSE/DESCRIPTION: This is an open label trial to collect long-term safety and tolerability data, including assessments of cardiac structure and function, during chronic dosing with CK3773274. A cardiac magnetic resonance (CMR) imaging sub-study will assess the effects of long-term dosing on cardiac morphology, function and fibrosis.
Please see section 1 of the full protocol
1 - 10 of 17
- 1
- 2
